Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 3,720,000 shares, a decrease of 10.8% from the October 31st total of 4,170,000 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average trading volume of 950,500 shares, the short-interest ratio is currently 3.9 days.

Grifols Trading Up 1.4 %

GRFS traded up $0.10 on Tuesday, reaching $7.23. 2,045,097 shares of the company’s stock were exchanged, compared to its average volume of 1,874,463. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols has a twelve month low of $5.30 and a twelve month high of $12.15. The company’s 50 day moving average is $8.73 and its 200-day moving average is $8.10.

Hedge Funds Weigh In On Grifols

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brandes Investment Partners LP lifted its holdings in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after buying an additional 1,481,924 shares in the last quarter. Black Creek Investment Management Inc. boosted its holdings in Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares during the last quarter. Armistice Capital LLC grew its stake in Grifols by 18.7% during the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares in the last quarter. Whitebox Advisors LLC increased its holdings in Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock worth $37,487,000 after purchasing an additional 1,519,093 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Grifols by 4.7% during the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after buying an additional 100,131 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.